

# Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/N425DFFCE9DEN.html>

Date: October 2021

Pages: 101

Price: US\$ 125.00 (Single User License)

ID: N425DFFCE9DEN

## Abstracts

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

### Novartis AG Key Recent Developments

Oct 07,2021: Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis

Sep 30,2021: Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

Aug 26,2021: The next generation of implantable drug delivery devices goes remote onboard the ISS

Jul 21,2021: Novartis Announces Q2 2021 Financial Results

Jul 21,2021: Novartis delivered strong Q2 performance, driven by momentum of key growth brands

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Novartis AG - Key Facts  
Novartis AG - Key Employees  
Novartis AG - Key Employee Biographies  
Novartis AG - Major Products and Services  
Novartis AG - History  
Novartis AG - Company Statement  
Novartis AG - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries  
Joint Venture

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Novartis AG - Business Description  
Business Segment: Innovative Medicines  
Overview  
Performance  
Key Stats  
Business Segment: Sandoz  
Overview  
Performance  
Key Stats  
Geographical Segment: Asia/Africa/Australasia  
Performance  
Geographical Segment: Canada and Latin America  
Performance  
Geographical Segment: Europe  
Performance  
Geographical Segment: The US  
Performance  
R&D Overview  
Novartis AG - Corporate Strategy  
Novartis AG - SWOT Analysis  
SWOT Analysis - Overview

Novartis AG - Strengths  
Novartis AG - Weaknesses  
Novartis AG - Opportunities  
Novartis AG - Threats  
Novartis AG - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES**

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Novartis AG, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Oct 07, 2021: Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis  
Sep 30, 2021: Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions  
Aug 26, 2021: The next generation of implantable drug delivery devices goes remote onboard the ISS  
Jul 21, 2021: Novartis Announces Q2 2021 Financial Results  
Jul 21, 2021: Novartis delivered strong Q2 performance, driven by momentum of key growth brands  
Jun 28, 2021: Novartis appoints Rob Kowalski as Chief People & Organization Officer  
Jun 25, 2021: Novartis Hellas S.A.C.I. and Alcon agree to pay over \$233 million combined to resolve criminal FCPA cases  
Jun 23, 2021: Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts  
Jun 23, 2021: Novartis and Hewlett Packard Enterprise join forces to advance Novartis

global health efforts

Jun 21, 2021: Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Novartis AG, Key Facts  
Novartis AG, Key Employees  
Novartis AG, Key Employee Biographies  
Novartis AG, Major Products and Services  
Novartis AG, History  
Novartis AG, Subsidiaries  
Novartis AG, Joint Venture  
Novartis AG, Key Competitors  
Novartis AG, Ratios based on current share price  
Novartis AG, Annual Ratios  
Novartis AG, Annual Ratios (Cont...1)  
Novartis AG, Annual Ratios (Cont...2)  
Novartis AG, Interim Ratios  
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Novartis AG, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios



## List Of Figures

### LIST OF FIGURES

Novartis AG, Performance Chart (2016 - 2020)

Novartis AG, Ratio Charts

Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

## I would like to order

Product name: Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/N425DFFCE9DEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N425DFFCE9DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970